Karsten Lindhardt, PhD
Karsten has more than 20 years of experience in the pharmaceutical industry (the last 12 as an executive). He is the CEO and founder of Biograil developing a drug delivery technology for effective oral delivery of biomacromolecules. Karsten managed to spin off Biograil from Egalet after securing Seed funding from a strong syndicate of experienced investors. Karsten started to explore this technology with his team when he was CSO of Egalet where he was also part of the executive management team making a successful IPO on NASDAQ NYC. Karsten and the team were responsible for the world’s first injection molded oral product Arymo ER to get FDA Approval. Through his career Karsten has worked in various biotech and pharma companies (Egalet, Curalogic, Prosidion, Ferring and Novo Nordisk) and has been involved in API upscaling, formulation development, pre-clinical screening and toxicology, phase 1, 2 and 3 clinical development, NDA, approval and launch, and business development pitching various technologies with great success. Karsten is the co-founder of Scantox, a fast-growing pre-clinical CRO, where he is part of the board.